IONAMIN
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASEPriority Review
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IONAMIN is an oral extended-release capsule small-molecule product approved in 1959 by UCB Pharma as an NDA. The specific indication and mechanism of action are not publicly documented in available data. This legacy product represents a long-established therapeutic option in its market segment.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely focused on margin protection and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IONAMIN currently shows zero linked job openings, reflecting its mature lifecycle stage and pending LOE. Career opportunities on this product are limited to specialized regulatory maintenance, compliance, and commercial wind-down roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on IONAMIN at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.